ALPHABET INC. INVESTMENT PORTFOLIO • Q3 2025
Google Ventures
Live tracking of Alphabet Inc.'s equity holdings managed by GV Management Company, Google LLC, CapitalG, and Verily Life Sciences. Based on SEC Form 13F-HR regulatory filings. Portfolio value: $2.41B (Q3 2025).
Total Portfolio Value
$2.4B
Holdings
37
Top 5 Concentration
63.1%
Q/Q Value Change
+12.8%
Sector Allocation
Portfolio Value Over Time
This shows portfolio VALUE (not returns), which includes both stock price changes AND new investments/divestments
Filing Information
Last Updated
November 6, 2025
Filing Period
Q3 2025
Period ended September 30, 2025
Portfolio Manager
Alphabet Inc.
Subsidiaries: GV, CapitalG
Next Filing
February 14, 2026
Q4 2025 (as of December 31, 2025)
Total Portfolio Value
$2.41B
Quarterly Change
+12.80%
Total Positions
37
Portfolio Holdings
Q3 2025 positions with current stock prices and quarterly changes
Data Source: 13F Filings
Visit gv.com →| Company | Ticker | Current Price | Shares (M) | Value ($M) | % Portfolio | Shares Q/Q | Shares Y/Y | 1Y Return |
|---|---|---|---|---|---|---|---|---|
AST SpaceMobile | ASTS | $49.11 | 8.9M | $439M | 18.2% | +0.4% | +5.2% | +235.1% |
Planet Labs | PL | $12.99 | 31.9M | $415M | 17.2% | +0.1% | +45.2% | +399.3% |
ARM Holdings | ARM | $141.33 | 2.0M | $277M | 11.5% | +0.0% | +3.2% | -12.5% |
Metsera | MTSR | $52.38 | 3.8M | $198M | 8.2% | +0.0% | -22.9% | +45.8% |
Revolution Medicines | RVMD | $46.73 | 4.1M | $193M | 8.0% | +0.0% | +0.7% | +15.2% |
Freshworks | FRSH | $11.78 | 16.2M | $191M | 7.9% | +0.0% | +0.1% | -28.4% |
Tempus AI | TEM | $80.65 | 1.6M | $125M | 5.2% | +0.0% | +19.2% | +67.4% |
GitLab | GTLB | $45.22 | 2.7M | $123M | 5.1% | +0.0% | +23.6% | -15.3% |
UiPath | PATH | $13.37 | 7.0M | $94M | 3.9% | +0.0% | +4.9% | -35.7% |
Prime Medicine | PRME | $5.56 | 16.6M | $92M | 3.8% | +195.7% | +74.3% | +18.6% |
DexCom | DXCM | $67.31 | 1.0M | $70M | 2.9% | +15.6% | -30.7% | -8.9% |
Maze Therapeutics | MAZE | $26.14 | 2.4M | $63M | 2.6% | +123.1% | +26.8% | +22.1% |
BridgeBio Oncology Therapeutics | BBOT | $11.70 | 2.8M | $33M | 1.4% | NEW | NEW | +22.5% |
Monte Rosa Therapeutics | GLUE | $36.67 | 0.6M | $22M | 0.9% | +20.0% | -25.0% | -18.5% |
Sana Biotechnology | SANA | $40.00 | 0.5M | $20M | 0.8% | +25.0% | -16.7% | +8.3% |
Figma | FIG | $50.00 | 0.2M | $11M | 0.5% | NEW | NEW | +17.8% |
Oscar Health | OSCR | $18.96 | 0.5M | $9.1M | 0.4% | -12.7% | -4.0% | +31.7% |
Beam Therapeutics | BEAM | $25.00 | 0.3M | $8M | 0.3% | +0.0% | +0.0% | -42.1% |
Relay Therapeutics | RLAY | $5.12 | 1.6M | $8.2M | 0.3% | +471.4% | +540.0% | +12.4% |
Vera Therapeutics | VERA | $29.17 | 0.2M | $7M | 0.3% | +0.0% | +20.0% | -19.2% |
Definitive Healthcare | DNTH | $20.00 | 0.2M | $4.2M | 0.2% | -34.4% | -30.0% | -25.6% |
Lyell Immunopharma | LYEL | $16.55 | 0.3M | $4.8M | 0.2% | +45.0% | +93.3% | -34.8% |
Foghorn Therapeutics | FHTX | $4.80 | 0.5M | $2.4M | 0.1% | +233.3% | +400.0% | -28.7% |
GeneDx | WGS | $120.00 | 0.0M | $2.4M | 0.1% | -75.0% | -60.0% | +28.9% |
Taysha Gene Therapies | TSHA | $3.28 | 0.6M | $2.1M | 0.1% | +966.7% | +3100.0% | +42.1% |
TScan Therapeutics | TCRX | $1.82 | 1.1M | $2M | 0.1% | +2650.0% | NEW | +38.7% |
Barinthus Biotherapeutics | BRNS | $1.27 | 1.5M | $1.9M | 0.1% | +7400.0% | NEW | +18.2% |
Spero Therapeutics | SPRO | $1.91 | 0.9M | $1.7M | 0.1% | NEW | NEW | +15.8% |
Tenaya Therapeutics | TNYA | $1.63 | 0.9M | $1.5M | 0.1% | NEW | NEW | -12.4% |
Hyperfine | HYPR | $1.44 | 0.9M | $1.3M | 0.1% | NEW | NEW | +8.7% |
Exact Sciences | EXAS | $65.00 | 0.0M | $1.3M | 0.1% | +0.0% | +0.0% | +14.7% |
Autolus Therapeutics | AUTL | $1.57 | 0.7M | $1.1M | 0.0% | +483.3% | +600.0% | -21.3% |
Fractyl Health | GUTS | $1.67 | 0.7M | $1.1M | 0.0% | +560.0% | +725.0% | +52.8% |
Alector | ALEC | $2.89 | 0.2M | $0.52M | 0.0% | +125.0% | +260.0% | -16.4% |
Quince Therapeutics | QNCX | $1.63 | 0.2M | $0.31M | 0.0% | +850.0% | NEW | +25.3% |
Fulcrum Therapeutics | FULC | $13.00 | 0.0M | $0.13M | 0.0% | +0.0% | NEW | +12.8% |
Repligen | RGEN | $125.00 | 0.0M | $0.05M | 0.0% | NEW | NEW | +8.4% |